Want to see YARW full AI Analyst Report?
Total Valuation
Yarrow Bioscience has a market cap or net worth of $270.67M. The enterprise value is $0.63.
Market Cap$270.67M
Enterprise Value$0.63
Share Statistics
Yarrow Bioscience has 9,437,693 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,437,693
Owned by Insiders16.35%
Owned by Institutions―
Financial Efficiency
Yarrow Bioscience’s return on equity (ROE) is -0.95 and return on invested capital (ROIC) is -107.15%.
Return on Equity (ROE)-0.95
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-107.15%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee57.00K
Profits Per Employee-2.67M
Employee Count10
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Yarrow Bioscience is ―. Yarrow Bioscience’s PEG ratio is 0.03.
PE Ratio―
PS Ratio43.53
PB Ratio0.89
Price to Fair Value0.89
Price to FCF-0.75
Price to Operating Cash Flow-1.32
PEG Ratio0.03
Income Statement
In the last 12 months, Yarrow Bioscience had revenue of 570.00K and earned -26.48M in profits. Earnings per share was -30.96.
Revenue570.00K
Gross Profit547.00K
Operating Income-29.75M
Pretax Income-26.73M
Net Income-26.48M
EBITDA-26.73M
Earnings Per Share (EPS)-30.96
Cash Flow
In the last 12 months, operating cash flow was -16.93M and capital expenditures 0.00, giving a free cash flow of -16.93M billion.
Operating Cash Flow-16.93M
Free Cash Flow-16.93M
Free Cash Flow per Share-1.79
Dividends & Yields
Yarrow Bioscience pays an annual dividend of $20.1, resulting in a dividend yield of 64.24%
Dividend Per Share$20.1
Dividend Yield64.24%
Payout Ratio-131.99%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change192.46%
50-Day Moving Average32.61
200-Day Moving Average20.94
Relative Strength Index (RSI)41.35
Average Volume (3m)99.79K
Important Dates
Yarrow Bioscience upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Yarrow Bioscience as a current ratio of 12.53, with Debt / Equity ratio of 0.00%
Current Ratio12.53
Quick Ratio12.53
Debt to Market Cap0.00
Net Debt to EBITDA0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Yarrow Bioscience has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Yarrow Bioscience EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -0.02.
EV to Sales1.38
EV to EBITDA-0.03
EV to Free Cash Flow-0.02
EV to Operating Cash Flow-0.02
Balance Sheet
Yarrow Bioscience has $22.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of $22.93M billion.
Cash & Marketable Securities$22.93M
Total Debt$0.00
Net Cash$22.93M
Net Cash Per Share$2.43
Tangible Book Value Per Share$32.46
Margins
Gross margin is 97.51%, with operating margin of -5219.12%, and net profit margin of -4646.14%.
Gross Margin97.51%
Operating Margin-5219.12%
Pretax Margin-4689.82%
Net Profit Margin-4646.14%
EBITDA Margin-4689.82%
EBIT Margin-4689.82%
Analyst Forecast
The average price target for Yarrow Bioscience is $57.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$57.00
Price Target Upside88.68% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast1.26%
EPS Growth Forecast48.11%